Phaseline

Targets › IL2RB

IL2RB (Interleukin-2 receptor subunit beta): drug programs, companies and trials

12 programs from 12 companies in 46 trials: 21 Phase 2, 21 Phase 1, 4 Phase 3; Oncology, Metabolic and endocrine, Immunology; next expected readout Nov 2026.

Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. (UniProt, P14784)

Open in Phaseline: the race on IL2RB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ImmunityBioNogapendekin Alfa Inbakicept (N803)
Interleukin-15 receptor agonist
IL2RG, IL2RB, IL15RAPhase 3NSCLC Stage IV; Long COVID; Platinum-resistant Ovarian Cancer; Relapsed B-Cell Non Hodgkin Lymphoma …Mar 2027
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDaclizumab (CD25)
Interleukin-2 receptor inhibitor
IL2RA, IL2RG, IL2RBPhase 3Graft Versus Host DiseaseMay 2028
CellTransBasiliximab
Interleukin-2 receptor inhibitor
IL2RA, IL2RG, IL2RBPhase 3Type 1 Diabetes Mellitus; Renal Transplant Rejection; Recurrent Hodgkin Lymphoma; Acute Lymphoblastic Leukemia–
Dana-Farber Cancer InstituteAldesleukin
Interleukin-2 receptor agonist
IL2RA, IL2RG, IL2RBPhase 2Chronic Graft-versus-host Disease; Acute Myeloid Leukemia; Platinum-resistant Ovarian Cancer; Chronic Graft Versus Host DiseaseNov 2026
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSAldesleukin
Interleukin-2 receptor agonist
IL2RA, IL2RG, IL2RBPhase 2Stage IV Colorectal Cancer; Head Neck Tumors; Mesothelioma, MalignantDec 2026
M.D. Anderson Cancer CenterAldesleukin
Interleukin-2 receptor agonist
IL2RA, IL2RG, IL2RBPhase 2Melanoma; Metastatic Melanoma; Metastatic Malignant Neoplasm in the LungOct 2027
Assistance Publique - Hôpitaux de ParisAldesleukin (ILT-101)
Interleukin-2 receptor agonist
IL2RA, IL2RG, IL2RBPhase 2Type 1 DiabetesNov 2027
AgonOxDP CD8 TIL KD
Interleukin-2 receptor agonist
IL2RA, IL2RG, IL2RBPhase 1HNSCCDec 2026
SanofiPegenzileukin
IL-2R beta/gamma agonist
IL2RG, IL2RBPhase 1Plasma Cell Myeloma RefractorySep 2027
National Cancer Institute (NCI)Recombinant Human Interleukin-15 (rhIL-15)
Interleukin-15 receptor agonist
IL2RG, IL2RB, IL15RAPhase 1NeuroblastomaJun 2028
H. Lee Moffitt Cancer Center and Research InstituteInterleukin-2 (IL-2)
Cytokine to support TIL expansion and activation
IL2RA, IL2RB, IL2RGPhase 1LymphocytesSep 2029
Alexander B Olawaiye, MDDenileukin Diftitox (E7777)
Elongation factor 2 inhibitor; Interleukin-2 receptor binding agent
EEF2, IL2RA, IL2RG, IL2RBPhase 1Epithelial Ovarian CancerMay 2030

Conditions

Acute Myeloid Leukemia (3) Platinum-resistant Ovarian Cancer (2) Long COVID (2) Melanoma (1) Metastatic Melanoma (1) Metastatic Malignant Neoplasm in the Lung (1) Plasma Cell Myeloma Refractory (1) Chronic Graft-versus-host Disease (1) Chronic Graft Versus Host Disease (1) Epithelial Ovarian Cancer (1) NSCLC Stage IV (1) Relapsed B-Cell Non Hodgkin Lymphoma (1)

Modalities

mixed (7), protein or peptide (4), small molecule (1)

Companies

M.D. Anderson Cancer Center (1) Sanofi (1) Dana-Farber Cancer Institute (1) Alexander B Olawaiye, MD (1) ImmunityBio (1) Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) National Cancer Institute (NCI) (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) Assistance Publique - Hôpitaux de Paris (1) H. Lee Moffitt Cancer Center and Research Institute (1) AgonOx (1) CellTrans (1)

Related targets

IL2RG (12) IL2RA (9) IL15RA (2) EEF2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.